The ASGE gave the ORBERA system a nod for meeting its Preservation and Incorporation of Valuable Endoscopic Innovations threshold standards for the treatment of obesity.
“ORBERA’s recognition by ASGE as the only endoscopic treatment that currently meets their predetermined efficacy threshold underscores the importance of ORBERA as a proven and effective non-surgical solution to help patients and their doctors fight obesity before their disease requires more invasive treatments,” said Todd Newton, CEO of Apollo Endosurgery.
More articles on gastroenterology:
FDA approves new CRC drug
15 things to know about gastroenterology for ASCs
Beyond patient care: The biggest challenges in GI
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
